New Drugs Bringing New Challenges to AML: A Brief Review.

Autor:	Yeoh ZH; Department of Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia., Bajel A; Department of Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia., Wei AH; Department of Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Department of Clinical Haematology, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia.; Division of Blood Cells and Blood Cancers, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2021 Oct 03; Vol. 11 (10). Date of Electronic Publication: 2021 Oct 03.
DOI:	10.3390/jpm11101003
Abstrakt:	The better understanding of the genomic landscape in acute myeloid leukaemia (AML) has progressively paved the way for precision medicine in AML. There is a growing number of drugs with novel mechanisms of action and unique side-effect profiles. This review examines the impact of evolving novel therapies on survival in AML and the challenges that ensue.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu